Zobrazeno 61 - 70
of 127
pro vyhledávání: ''
Autor:
Satoshi Yoda, Aaron N. Hata, Leila Dardaei, Manrose Singh, Jeffrey A. Engelman, Alice T. Shaw
Publikováno v:
Cancer Research. 77:3144-3144
Anaplastic lymphoma kinase (ALK) rearrangements are important therapeutic targets in non-small cell lung cancer. They are currently treated with the first-generation ALK inhibitor crizotnib followed by more potent, second-generation ALK inhibitors, s
Autor:
Solene Geraudie, Alan Cuthbertson, Dominik Mumberg, Urs B. Hagemann, Olav B. Ryan, Jenny Karlsson, Dessislava Mihaylova, Derek Grant, Bård Indrevoll, Christoph A. Schatz, Alexander Kristian, Christine Ellingsen, Carl Friedrich Nising, Roger M. Bjerke, Uta Wirnitzer
Publikováno v:
Cancer Research. 77:5859-5859
The human epidermal growth factor receptor 2 (HER2) is encoded by the proto-oncogene c-erbB-2 and initiates downstream signaling pathways leading to cell proliferation and tumorigenesis. HER2 is overexpressed in several cancer (Ca) types and is one o
Publikováno v:
Cancer Research. 75:P3-04
Background: Co-morbidity of thyroid disease and breast cancer has been recognized for over a century. Up to two-thirds of women with breast cancer have clinical or occult thyroid disease, as compared to one fifth of unaffected females. Thyroid diseas
Autor:
Qiping Zhao, Gilbert A. Keller, Dan C. Maneval, Steve Rowe, Chunmei Zhao, Kim Phan, Michael Shepard, Ryan J. Osgood, Robert J. Connor, Lei Huang, Xiaoming Li, Gregory I. Frost, Curtis B. Thompson, Jason Parise, Sanna Rosengren, Christopher D. Thanos, Ge Wei, Jessica Cowell, Bob Veneziale
Publikováno v:
Cancer Research. 76:B32-B32
The epidermal growth factor (EGF) signaling pathway relies on recognition by its receptor, EGFR, and subsequent downstream signaling by the KRAS and BRAF proteins to relay proper proliferative, migratory, and angiogenic functions. Cancers with activa
Autor:
Brenda Diergaarde, Beatriz Kanterewicz, Shira Abberbock, Autumn Gaither-Davis, Laura P. Stabile, Brenda F. Kurland, Mary E. Rothstein
Publikováno v:
Cancer Research. 76:LB-079
Obesity has been shown to increase breast cancer risk by causing inflammation through altered estrogen signaling. Whether obesity plays a similar role in lung carcinogenesis is currently not known. However, the role of estrogen signaling in the devel
Autor:
Christi A. Walter, Jessica A. Zavadil
Publikováno v:
Cancer Research. 76:3595-3595
Eighty percent of hepatocellular carcinoma (HCC) within the USA is diagnosed late when chemotherapy provides only 2 months increased survival. We fortuitously found that treatment with an alkylating agent, methylnitrosurea (MNU), prior to tumorigenes
Publikováno v:
Cancer Research. 76:2617-2617
The response to ultraviolet (UV) radiation is the primary etiologic factor leading to carcinogenesis of the skin. The effects of UV radiation on the skin is generally transient, but the long term consequences can be carcinogenic. Despite growing publ
Autor:
Rafael Rosell, Mike Burbridge, Cattan Valérie, Jordi Codony-Servat, Cristina Teixidó, Carles Codony-Servat, Jordi Bertran-Alamillo, Miguel Angel Molina
Publikováno v:
Cancer Research. 76:336-336
Background: Aberrant activity of MET, FGFR1 and AXL has been associated with development of resistance to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) patients. S49076 is a potent ATP-competitive tyrosine kinase inhibitor (TKI)
Autor:
Arnold M. Schwartz, Erika Ginsburg, Saurabh Kirolikar, Sidney W. Fu, Patricia E. Berg, Samuel J. Simmens
Publikováno v:
Cancer Research. 76:2024-2024
BACKGROUND. BP1 is a member of the homeobox gene family of transcription factors. Our recent studies have shown that BP1 overexpression increases cell survival, aggressiveness and metastasis in breast cancer cells. BP1 protein is expressed in 80% of
Autor:
Ashok Srinivasan, James L. Wade, Thomas J. George, Marc Buyse, Jodi A. Kanyuch, Ashwin Reddy Sama, Norman Wolmark, S. Rim Kim, Ding Wang, Kay L. Pogue-Geile, James J. Lee, Samuel A. Jacobs, Philip J. Stella, Carmen J. Allegra
Publikováno v:
Molecular Cancer Therapeutics. 14:C46-C46
Background Multiple mechanisms may account for de novo and acquired resistance to Cmab. One mechanism, HER2 amplification, promotes heterodimer formation with HER3, bypassing EGFR blockade and resulting in downstream signaling. Bertotti reported HER2